IAG CEO Dr. Olga Kubassova to Speak on Panel at Biotech Investment Showcase, 22-23 May, London, UK

Slider with alias news slider not found.

IAG CEO Dr. Olga Kubassova to Speak on Panel at Biotech Investment Showcase, 22-23 May, London, UK

Dr. Olga Kubassova, IAG CEO will be speaking on a panel addressing leading-edge funding, investment and partnering models at the Biotech Investment Showcase and Start-Up Slam. Dr. Kubassova will discuss the challenges biotechnology companies face in the industry and will explain IAG’s unique approach to solving these problems.

Dr. Diana Roettger, Head of Scientific and Medical Affairs and Lead Bio-Partnering analyst will also attend the conference to meet with different biotechnology companies and identify potential opportunities for strategic financial investment and collaboration.

To schedule a meeting or learn more about Dr. Kubassova’s Panel Discussion, please email contact@ia-grp.com

About Biotech Investment Showcase and Start-up Slam

The 2018 Biotech Investment showcase is the UK and Europe’s most focused and leading-edge funding, investment and partnering forum in the biotech sector, hosting over 200 attendees. Leading VC funds, investors, hedge funds, emerging successful biotech spinoffs, early stage biotech discovery and clinical companies and KOLs in the sector will be attending this one of a kind showcase event on the 22nd & 23rd May 2018 in London. The event will help to identify key technological and scientific investment areas and offers a unique networking, partnering and business development opportunity for those involved. To find out more about this conference click here.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin